Castle Creek Biosciences

Castle Creek Biosciences is a private late-stage regenerative medicine and cell/gene therapy company focused on severe genetic skin, connective tissue, and selected metabolic diseases. The company is best known for D-Fi (FCX-007; dabocemagene autoficel), an autologous fibroblast-based gene therapy in a registrational Phase 3 study for dystrophic epidermolysis bullosa. Castle Creek built its core platform around ex vivo lentiviral modification of a patient’s own dermal fibroblasts and later expanded into in vivo lentiviral gene therapy through its acquisition of Novavita Thera. The company also maintains in-house cGMP commercial-scale manufacturing capabilities in Exton, Pennsylvania. Castle Creek is a Paragon Biosciences portfolio company and has positioned itself around re-dosable, personalized gene therapies for rare diseases with high unmet need.